A recent systematic review and meta-analysis observed that adults with obesity or overweight who were administered GLP-1 analogs for at least 12 weeks, showed a significant overall improvement in excess weight loss when compared to a placebo, with a weighted mean difference of 3.11 kg [28]. Here, GLP1R is linked to obesity disorder.